Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels
1 other identifier
observational
90
1 country
1
Brief Summary
The serum procalcitonin levels are important during infections and sepsis. The investigators aimed to assess its predictive value in terms of post-cesarean wound infection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 2, 2017
CompletedFirst Submitted
Initial submission to the registry
July 17, 2017
CompletedFirst Posted
Study publicly available on registry
July 21, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 29, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 8, 2017
CompletedOctober 24, 2017
October 1, 2017
5 months
July 17, 2017
October 22, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Serum procalcitonin levels in participants who developed wound infection after cesarean sections
Serum procalcitonin levels will be measured in participants who will develop post-cesarean wound site infections. The serum procalcitonin levels will be compared in subgroups who need secondary suture and those who don't require suturing
5 months
Study Arms (2)
No secondary suture
The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
Secondary suture
The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
Interventions
serum procalcitonin level will be measured in both groups.
Eligibility Criteria
The participants are post-cesarean patients who developed surgical site infections.
You may qualify if:
- who developed surgical site infection after their cesarean sections.
- years old
You may not qualify if:
- history of chorioamnionitis and premature rupture of membranes
- urinary tract infections
- any infectious condition other than surgical site infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kanuni SSRTH
Istanbul, 34303, Turkey (Türkiye)
Related Publications (4)
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013 May;13(5):426-35. doi: 10.1016/S1473-3099(12)70323-7. Epub 2013 Feb 1.
PMID: 23375419BACKGROUNDTakakura Y, Hinoi T, Egi H, Shimomura M, Adachi T, Saito Y, Tanimine N, Miguchi M, Ohdan H. Procalcitonin as a predictive marker for surgical site infection in elective colorectal cancer surgery. Langenbecks Arch Surg. 2013 Aug;398(6):833-9. doi: 10.1007/s00423-013-1095-0. Epub 2013 Jun 20.
PMID: 23784676BACKGROUNDErenel H, Yilmaz N, Oncul M, Acikgoz AS, Karatas S, Ayhan I, Aslan B, Tuten A. Usefulness of Serum Procalcitonin Levels in Predicting Tubo-Ovarian Abscess in Patients with Acute Pelvic Inflammatory Disease. Gynecol Obstet Invest. 2017;82(3):262-266. doi: 10.1159/000449161. Epub 2016 Sep 3.
PMID: 27592364RESULTAslan Cetin B, Aydogan Mathyk B, Koroglu N, Temel Yuksel I, Konal M, Erenel H, Atis Aydin A. Serum procalcitonin levels in incisional surgical site infections requiring a secondary suture after cesarean sections. J Matern Fetal Neonatal Med. 2019 Dec;32(24):4108-4113. doi: 10.1080/14767058.2018.1481949. Epub 2018 Jun 20.
PMID: 29804483DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Alev Atis, MD,ObGyn
Kanuni Sultan Suleyman Training and Research Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 2 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD,ObGYN
Study Record Dates
First Submitted
July 17, 2017
First Posted
July 21, 2017
Study Start
May 2, 2017
Primary Completion
September 29, 2017
Study Completion
October 8, 2017
Last Updated
October 24, 2017
Record last verified: 2017-10
Data Sharing
- IPD Sharing
- Will not share